The role of HLA antibodies in SCT has drawn increasing attention because of the significantly increased number of patients who receive HLA-mismatched SCT, including cord blood transplantation, haploidentical SCT and unrelated SCT. Technical advancements in the methods of HLA Ab testing have realized rapid, accurate and objective identification, as well as quantification of specific HLA antibodies. Recent clinical studies have suggested that the presence of donor-specific HLA antibodies (DSA) in patients is associated with graft failure in HLA-mismatched SCT when the above-listed stem cell sources are used and results in different impacts. Of note, most of the 'HLA-matched' unrelated SCT actually involve HLA mismatches in HLA-DP and the presence of antibodies against this locus has been reported to be associated with graft failure. Thus, HLA Ab should be examined as a work-up for all patients who undergo SCT from 'alternative donors.' The simplest route for preventing HLA Ab-mediated graft failure in Ab-positive patients is to avoid donors who possess the target Ag of HLA antibodies. If SCT from such donors must be performed, treatment for DSA before SCT may improve the chances of successful donor engraftment.
INTRODUCTION
The clinical significance of HLA antibodies is well recognized in the field of transfusion medicine. In particular, the presence of HLA antibodies in patients is one of the major causes of platelet transfusion refractoriness. 1 Moreover, HLA antibodies in blood products have been shown to be a major cause of transfusionrelated acute lung injury. 2 --5 Although several early studies on HLA haploidentical-SCT in the 1980s implicated a role of HLA antibodies in graft failure, 6, 7 it has been generally recognized to have a minor role in graft failure when compared with cellular immunity. However, preformed recipient HLA antibodies have drawn increasing attention because of their potential role in graft failure. Two major reasons account for this revision on the role of HLA antibodies in graft failure. One is the rapid increase in the number of HLA-mismatched SCT, including cord blood transplantation (CBT), haploidentical SCT and unrelated SCT. The other is a technical advancement in the methods of HLA Ab testing, which has realized a rapid, accurate and objective identification and quantification of specific HLA antibodies.
In the kidney transplant setting, HLA Ab testing has long been a part of the routine work-up for patients. Pioneering work by Terasaki et al. 8 and numerous further studies have demonstrated that donor-specific HLA antibodies (DSA) are involved in the mechanism of hyperacute rejection, acute rejection, 9 and chronic rejection 10 of renal allograft. Moreover, recent studies have suggested that intervention for DSA can prevent Ab-mediated graft rejection. 11 In this review, we outline the role of HLA antibodies in SCT. First, we briefly describe the methods for HLA Ab testing and the basics of HLA antibodies. Afterwards, we discuss the clinical relevance of preformed HLA antibodies in patients who undergo SCT and then describe future directions.
METHODS OF HLA AB TESTING
Commonly used methods of HLA Ab testing are shown in Table 1 . They can be largely categorized into cell-based assays and solidphase immunoassays. These two types of assays are used for different purposes and significantly differ in their sensitivities.
Cell-based assays Cell-based assays are used for crossmatch tests and include two major methods: the lymphocyte cytotoxicity test (LCT), which examines complement-dependent cytotoxicity, and the flow cytometry (FCM)-based Ab-binding assay. The anti-human-globulin-LCT (AHG-LCT) is a modified LCT assay that was developed to improve sensitivity. LCT/AHG-LCT has been the gold standard for decades, but its utility has been reduced by the development and commercial availability of solid-phase immunoassays. The major disadvantages of cell-based assays are logistical (that is, the requirement for fresh lymphocytes from donors and controls) and technical difficulties. In fact, fresh donor lymphocytes are unavailable for patients who undergo CBT. Further, the results can be confounded by the presence of non-HLA-specific antibodies, and the differentiation of antibodies specific for class I or class II requires the removal of class I-specific antibodies. Moreover, cell-based assays require days or even weeks for testing and data analysis. On the other hand, cell-based assays have an advantage over solid-phase immunoassays in having a remarkably lower cost. Moreover, cell-based assays allow the detection of native HLA Ags and are therefore not associated with the issues regarding solid-phase immunoassays that use denatured or recombinant HLA Ags discussed below.
Solid-phase immunoassays Solid-phase immunoassays enable the determination of Ab specificity and the quantification of Ab levels. Moreover, these assays enable retrospective analysis of HLA antibodies using the frozen samples. Three major methods of solid-phase immunoassays are used: ELISA, fluoroanalysis of FCM-based multianalyte beads, and fluoroanalysis of Luminex-based multianalyte beads (Luminex, Austin, TX, USA). Of these, the FCM-and Luminex-based assays are the ones most commonly used in the field of transfusion medicine because of their high sensitivity. The Luminex-based assay was used in most of the recent studies in SCT patients, as will be reviewed below, probably because of its advantage in terms of high throughput. For each of these methods, the targets are in the form of mixed Ags, panels of phenotypes (PRA), or panels of single Ags with class I and class II Ags separated. Although isolated HLA Ags are coated onto microspheres in Luminex-based mixed-Ag and PRA assays, recombinant Ags are coated onto microspheres in the Luminexbased single-Ag assay. Ab levels can be quantified by a mean/ median fluorescence channel shift in the FCM-based assay and by a mean/median fluorescence intensity (MFI) in the Luminex-based assay. The high sensitivity of the Luminex-based assays has raised an issue regarding the threshold of clinically relevant Ab levels. Several previous studies in the kidney transplant setting have suggested that lower levels of antibodies are not associated with the risk of graft rejection. 12 However, the cutoffs of Ab positivity have not been standardized and vary remarkably among studies.
BASICS OF HLA ANTIBODIES
The prevalence of HLA antibodies caused by alloimmunization Causes of alloimmunization include pregnancies, blood transfusion and allogeneic transplantation. The effects of pregnancies on alloimmunization have been examined in studies investigating the prevalence of HLA antibodies in blood donors. 3,13 --15 In one of the largest studies, 7920 volunteer donors were tested for the presence of HLA class I and II antibodies using a Luminex-based mixed-Ag assay. 15 The prevalence of HLA antibodies was similar in non-transfused male (1.0%) and transfused male donors (1.7%, P ¼ 0.16). Meanwhile, HLA antibodies were detected in 17.3% of all female donors and in 24.4% of those with a history of previous pregnancy. The prevalence of HLA antibodies increased in female donors based on the number of pregnancies: 1.7% (0), 11.2% (1), 22.5% (2), 27.5% (3) and 32.2% (4 or more pregnancies, Po0.0001). The low prevalence of HLA antibodies in transfused males in this study population is probably attributable to the long interval (median 22 years) between a previous transfusion history and blood donation. Other studies that evaluated the presence of the HLA Ab within several months of transfusion showed a much higher prevalence, up to 50%. 16 --18 Seftel et al. 19 reported the result of a retrospective analysis of alloimmunization in 617 patients with acute leukemia and/or those who underwent SCT. HLA antibodies were tested using an AHG-LCT assay. Alloimmunization occurred in 19% of patients who received blood products with post-storage leukoreduction and in 7% of those who received blood products with pre-storage and post-storage leukoreduction.
The prevalence of HLA antibodies in patients who underwent SCT is shown in Table 2 . The prevalence varied between 20 and 40% among studies. This variation may be attributable to the differences in the cutoff value of Ab positivity, as well as the patient backgrounds. The prevalence of HLA antibodies in the female patients was higher (31 --44%) than that in the male patients (11 --13%). Moreover, Ciurea et al.
11 also showed that the prevalence of HLA antibodies was not significantly different between female patients with no pregnancies and male patients and that the prevalence increased in female patients based on the number of pregnancies. These results confirm that pregnancies and the transfusion of blood products are the major causes of alloimmunization in transplant populations.
HLA Ag expression in blood cells HLA Ag expression in the different blood cell fractions is shown in Table 3 . 20 --25 The pattern of HLA Ag expression in hematopoietic precursor cells is important when considering the role of HLA antibodies in graft failure after SCT. Ottmann et al. 22 reported that approximately 95% of assayable erythroid, myeloid and multipotential progenitor cells expressed HLA-DR, whereas HLA-DQ Ags were undetectable. Moreover, HLA-DR and HLA-DP Ags were co-expressed on 61% of these progenitor cells, predominantly those expressing HLA-DR at high intensity.
Cross-reactivity of antibodies Recognizing the cross-reactivity of HLA antibodies is clinically relevant when interpreting the results of Ab testing. HLA antibodies target immunogenic amino acids (that is, epitopes) in allogeneic mismatched HLA. Cross-reactivity of HLA antibodies commonly occurs as a result of the sharing of so-called 'public epitopes' by several HLA Ags. 26 HLA Ags belonging to the same cross-reactive group share public epitopes 27, 28 and thus can be detected as targets of a single clone of HLA antibodies. Previous studies have shown that specific epitopes have higher immunogenic capacity than others and can determine the production of a spread Ab pattern. 29 Moreover, previous studies have shown that the immunogenic epitopes of HLA Ags were located mainly on the alpha 1 helix, which forms a peptide-binding cleft. 
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Natural antibodies
The introduction of sensitive solid-phase immunoassays, particularly the Luminex-based single-Ag assay, resulted in the frequent detection of low-level antibodies in non-transfused males and even in cord blood. 31 These antibodies have been termed 'natural antibodies.' In contrast to HLA antibodies that are detected in parous woman or transfused patients, many of these antibodies were directed against a limited number of rare HLA Ags, indicating these antibodies were unlikely to have arisen as a result of allogeneic Ag exposure. 32 The immunizing Ags and events that may lead to the production of these antibodies remain uncertain. Bacterial Ags that are cross-reactive with HLA have been reported to be possible immunizing Ags. 33, 34 Other plausible immunizing Ags include polypeptides from ingested foods and inhaled allergens. Importantly, the majority of targeted epitopes consisted of hidden amino acids that are believed to be inaccessible in the intact form of the HLA Ags. Indeed, 'natural antibodies' detected in renal allograft recipients were not predictive of graft failure. 35 The clinical relevance of 'natural antibodies' in SCT is also questionable but remains to be determined.
THE ROLE OF ANTIBODIES IN ANIMAL BMT MODELS
Nagata et al. demonstrated in a murine BMT model that alloreactive memory T cells and donor-specific antibodies independently function to reject donor BM in sensitized recipients. Moreover, Xu et al. 36 showed that donor-specific antibodies are the dominant barrier to engraftment and that T-cell-mediated cellular immunity has a less formidable role in rejection. 37 Adoptive transfer of serum from sensitized mice was shown to abrogate engraftment in secondary naïve recipients. Strikingly, none of the strategies directed primarily at T-cell alloreactivity enhanced engraftment in sensitized mice. Taylor et al. 38 confirmed that preformed donor-specific antibodies, not primed T cells, are the major barrier for engraftment in allosensitized recipients. Interestingly, Ab-mediated rejection occurs very rapidly (o3 h) in primed recipients, whereas T-cell-mediated rejection in nonprimed mice took more than 6 days. The study also demonstrated several clinically relevant findings, including the effectiveness of a combination of using high BM cell dose, host T-cell depletion and high-dose murine Ig in achieving engraftment in sensitized recipients. The strategy of intra-BM injection has been shown to promote engraftment in non-sensitized recipients but did not improve engraftment in sensitized recipients.
On the other hand, Storb questions the primary role of preformed antibodies suggested by these murine studies. 39 In earlier canine studies in the 1970s, no correlation was found between humoral anti-donor immunity and rejection in a setting where cellular immunity was blunted. 40, 41 Hence, one could conceivably argue that antibodies are simply surrogate markers for cellular immunity and that cellular immunity is the actual major barrier to engraftment. The reasons for the differences in results among mice and larger randomly bred mammals were not obvious but might include differences in preparative conditioning and the numbers of transplanted hematopoietic cells.
IMPACT OF HLA ANTIBODIES ON ENGRAFTMENT IN CLINICAL SETTINGS
Cord blood transplantation As described above, animal studies have indicated that the impact of HLA antibodies may vary according to the conditioning regimens and the numbers of transplanted cells. In this respect, engraftment after CBT is most likely to be affected by preformed HLA antibodies in patients. 42 Takanashi et al. 43, 44 have indeed shown that DSA have a major impact on engraftment after CBT (Table 2) . They examined the impact of DSA with retrospective Role of HLA antibodies in SCT S Yoshihara et al tests in 386 patients who received their first Allo-SCT with a myeloablative conditioning regimen, using a single unit of CB. 44 The plasma/sera samples of the patients were screened for the presence of HLA antibodies with FCM-based PRA tests. Positive samples were further tested for the specificity of the Ab using Luminex-based PRA or single-Ag analysis. A MFI41000 was considered to be positive. The cumulative incidence of neutrophil recovery 60 days after CBT was 83% in the Ab-negative patients; 73% for non-DSA-positive patients, who had HLA antibodies that did not correspond to donor HLA Ags; and only 32% for the DSApositive patients (Po0.0001). With multivariate analysis, the DSApositive patients had a significantly lower neutrophil recovery and platelet recovery than the ab-negative patients.
In a similar context, Cutler et al. 45 demonstrated that the presence of DSA is associated with an increased incidence of graft failure after double unit CBT. They examined the effect of DSA in 73 patients who received double-unit CBT with myeloablative or reduced-intensity conditioning. Following screening testing with Luminex-based mixed-Ag assays, the positive samples were submitted to single-Ag assays. A positive test for HLA Ab was defined as an increase in MFI41000. The incidence of graft failure in patients without DSA, with DSA directed against a single CB unit (n ¼ 11), or DSA directed against both CB units (n ¼ 7) was 5.5%, 18.2% and 57.1%, respectively (P ¼ 0.0001). Interestingly, the DSA level measured by MFI correlated with the occurrence of graft failure. The median MFI among 12 DSA-positive patients without graft failure was 1850, whereas it was 17 650 in the six DSApositive patients who experienced graft failure (P ¼ 0.039).
In contrast to these two reports, Brunstein et al. 46 reported that the cumulative incidence of engraftment was not affected by the presence of DSA in patients undergoing double unit CBT. They evaluated the impact of HLA antibodies on engraftment and unit predominance in 126 patients who received double unit CBT with myeloablative or reduced-intensity conditioning. HLA Ab specificities were determined using sequential testing. Following screen testing with Luminex-based mixed-Ag assays, the positive samples were submitted to single-Ag assays. MFI4500 was defined as positive. Eighteen patients were identified as having DSA corresponding to at least 1 of 2 CB units. Overall, nine of twelve patients with DSA against one of the two CB units and five of six patients with DSA against both units engrafted. The cumulative incidence of engraftment was similar in patients with and without DSA (83% vs 78%). The inconsistency in the results with the other two reports may be attributable to the different thresholds for the definition of DSA positivity (MFI4500 vs MFI41000).
Haploidentical SCT Much greater numbers of stem cells are infused into patients in haploidentical SCT compared with CBT. Ciurea et al. 47 demonstrated DSA nevertheless have a major impact on engraftment in patients who received haploidentical SCT with CD34-positive cell selection as a means of T-cell depletion from the graft. They tested 24 consecutive patients for the presence of HLA antibodies by testing the patients' sera with Luminex-based single-Ag assays. Three of 4 (75%) pretransplant DSA-positive patients (MFI41500) failed to engraft, compared with 1 of 20 (5%) DSA-negative patients (P ¼ 0.008).
In unmanipulated haploidentical SCT, the risk of graft failure is inherently lower than that of T cell-depleted SCT. Yoshihara et al. 48 demonstrated that DSA is still relevant for engraftment in patients who underwent unmanipulated haploidentical SCT. However, the impact appears to be smaller than that of CBT and T-cell-depleted haploidentical SCT. They prospectively examined HLA antibodies using the Luminex-based single-Ag assay for 79 adult patients undergoing unmanipulated haploidentical SCT. Patients were defined as DSA-positive when they had HLA antibodies with MFI45000, corresponding to the mismatched donor HLA Ag. The cumulative incidence of neutrophil recovery was significantly lower in the pretransplant DSA-positive patients than in DSAnegative ones (61.9% vs 94.4%, P ¼ 0.026). Notably, three of five patients with high levels of DSA (MFI410 000) had graft failure.
Unrelated SCT A number of studies have shown the effects of HLA matching on the clinical outcome in unrelated SCT. 49 --53 Nevertheless, recent National Marrow Donor Program analyses suggest that greater than 50% of unrelated SCT are mismatched for at least one classic HLA-A, B, C or DRB1 locus. In addition, mismatching at HLA-DP is observed in approximately 88% of all unrelated SCT. Notably, HLA-DP has been shown to be expressed on hematopoietic precursor cells, as described above.
Spellman et al. 54 conducted a case --control study to retrospectively evaluate the effect of preexisting DSA on engraftment in unrelated SCT. They tested pretransplant sera from graft failure patients (n ¼ 37) and a matched case-control cohort (n ¼ 78) by Luminex-based single-Ag assays or FCM-based single-Ag assays. Samples were considered to be positive for specific HLA Ags based on an MFI42000 in Luminex-based assays or a mean fluorescence channel shift of more than 40 in FCM-based assays. The majority of the patients received BMT after myeloablative conditioning. Among the 37 failed transplantations, nine (24%) recipients possessed DSA against HLA-A, B and/or DP, compared with only one (1%) of 78 controls. Therefore, the presence of DSA was significantly associated with graft failure (Po0.001). In particular, antibodies against HLA-DP were quite prominent and were present in 60% of Ab-positive failures.
Moreover, Ciurea et al. 55 evaluated the impact of HLA antibodies against HLA-DP in 'matched' unrelated SCT. The presence of HLA antibodies was determined in 592 patients who underwent unrelated SCT with myeloablative or reducedintensity conditioning. Luminex-based single-Ag assay was used for DSA identification; MFI4500 was considered to be positive. HLA antibodies were detected in 116 patients (20%), including 20 patients (3.4%) with anti-DPB1 antibodies. The incidence of graft failure in patients with DSA was significantly higher (38%) than that in patients without DSA (2.7%, P ¼ 0.0014). Interestingly, they 20 Piacibello et al. 21 Ottmann et al. Role of HLA antibodies in SCT S Yoshihara et al evaluated the expression levels of HLA Ags on progenitor cell surfaces and demonstrated that HLA-DP was significantly less expressed on normal CD34 þ cells compared with HLA class I Ags (HLA-A, B, C) (median 36.1% vs 99.9%, respectively; Po0.001). Thus, they attributed the smaller impact of DSA on engraftment in unrelated SCT, as compared with their previous experience with T-cell-depleted haploidentical SCT, 47 to a lower expression of HLA-DP Ags on the CD34 þ cell surface.
PREVENTION OF AB-MEDIATED GRAFT FAILURE Donor selection
The above-reviewed clinical studies suggest the clinical implication of HLA Ab testing as a work-up for patients who undergo HLA-mismatched SCT, including CBT, haploidentical SCT and unrelated SCT. Of note, patients who undergo 'HLA-matched' unrelated SCT are also indicated for Ab testing because of the potential presence of HLA antibodies against HLA-DP. When HLA antibodies that target HLA Ags that are not routinely typed (for example, HLA-DP) are detected in patients, HLA typing of their donors for those loci should be additionally performed, in order to determine whether these antibodies are donor-specific or not.
The simplest route for preventing HLA Ab-mediated graft failure in Ab-positive patients is to avoid donors who possess the target Ag of HLA antibodies. Successful engraftments after CBT using this strategy have already been reported in several papers. 56, 57 Nevertheless, this strategy is not always available. In haploidentical SCT, particularly in the settings of offspring-to-mother SCT, avoiding donors with HLA Ags corresponding to HLA antibodies is often difficult. 48 This difficulty is attributable to alloimmunization during pregnancy, a period when antibodies are generated against HLA Ags of the offspring.
Treatment of HLA antibodies before SCT Treatment options for preformed HLA antibodies are summarized in Table 4 . These options can be largely categorized as (1) depletion of B cells (rituximab) or Ab-producing cells (bortezomib), (2) depletion of preformed antibodies (plasma exchange and platelet transfusion from donors with HLA Ags corresponding to antibodies), and (3) abrogation of cytotoxic reactions caused by antibodies (high-dose i.v. Ig and eculizumab). The efficiency of each treatment option remains unclear because of the small number of reported cases ( Table 5 ). The combined use of these treatments makes it further difficult to evaluate the efficiency of each treatment option.
Previous studies and case reports have demonstrated the effect of plasma exchange in reducing Ab levels. 47,58 --60 Platelet transfusion from donors having DSA-corresponding HLA Ags, 48, 61 or transfusion of irradiated donor lymphocytes 58 also result in the rapid elimination of DSA through the mechanism of Ab absorption. Nevertheless, these strategies should be noted as producing only a transient effect because of their inability to prevent the production of new antibodies. In fact, Ab levels can rebound in a week after plasma exchange. 48 Thus, these strategies should be performed immediately before transplantation. In this respect, plasma exchange is often challenging to perform during or after preconditioning treatments because of the risks associated with the procedure. In contrast, platelet transfusion has the advantage of being a simple procedure but has an inherent lack of effectiveness for class II antibodies due to the lack of class II Ag expression on platelets.
Rituximab has been used in several cases with the aim of depleting memory B cells, but its effectiveness in reducing the DSA levels remains uncertain. 47, 48, 61 Recently, bortezomib has received more attention in the kidney transplant setting because of studies showing its direct elimination of Ab-producing plasma cells and its ability to prevent Ab-mediated graft rejection. 62, 63 However, to date, its use in SCT patients has scarcely been reported. 48 High-dose i.v. Ig has multiple immunomodulatory effects, including enhanced clearance of antibodies, complement modulation and inhibition of FcR-mediated clearance of Ab-bound cells. 64 High-dose i.v. Ig has been widely used in solid-organ transplantation, but so far its use in SCT patients has also scarcely been reported. 60 Eculizumab is a humanized MoAb directed against the terminal complement protein C5 and is approved in many countries for the treatment of paroxysmal nocturnal hemoglobinuria. Eculizumab has also received recent attention in the kidney transplant setting for the prevention of Ab-mediated rejection. 63 However, murine studies have indicated that complement-mediated lysis is unlikely to have a major role in the mechanism of Ab elimination of donor hematopoietic stem cells. 38 
FUTURE DIRECTIONS
Although further studies are needed to confirm the role of HLA antibodies in graft failure, the studies reviewed above have suggested that HLA antibodies should be examined as a part of the pretransplant work-up for all patients who undergo SCT from 'alternative donors'. Standardization of the Ab testing and determination of the cutoffs (possibly according to the stem cell sources) are urgently needed. Treatment algorithms for DSA should also be established. In the Hyogo College of Medicine, all patients who undergo CBT or haploidentical SCT are tested for HLA Ab as a work-up in collaboration with the HLA laboratory. The Luminex-based PRA assay is used for screening, and the Luminexbased single-Ag assay is used for the specification and quantification of antibodies. CB units that have HLA Ags corresponding to HLA antibodies with MFI41000 are excluded from candidates. In the settings of unmanipulated haploidentical SCT with our protocols, 65, 66 donors that have HLA Ags corresponding to HLA antibodies with MFI45000 are avoided. If haploidentical SCT from such donors must be performed, patients are treated for DSA to improve the chances of successful donor engraftment.
The studies on HLA antibodies in SCT patients have almost exclusively focused on IgG HLA antibodies. However, recent studies in the kidney transplant setting have suggested a role for IgM HLA antibodies and non-HLA alloantibodies, such as antibodies against MHC class I-related chain A (MICA) molecules in allograft rejection. 67, 68 Future studies on the role of IgM HLA antibodies and MICA antibodies in SCT are warranted.
Moreover, preformed DSA in patients possibly affect the clinical course after SCT, in addition to increasing the risk of graft failure. Interestingly, the above-reviewed study by Cutler et al. 45 showed that no patient with DSA developed acute GVHD, whereas 23.6% of patients without DSA had grades II --IV acute GVHD after double unit CBT. Double unit CBT has been reported to be associated with a higher incidence of acute GVHD than single unit CBT. 69 One hypothesis linking their findings to the disparities in GVHD incidence in this setting is that patients with DSA more frequently had hematopoiesis derived solely from one of the two transplanted UCB units. Alternatively, the effects of DSA on donor immunocompetent cells, such as T lymphocytes, may also be a target for future studies.
Finally, the presence of HLA antibodies in donors may also have some clinical implications. In fact, frequent detection of HLA antibodies in patients undergoing SCT from Ab-positive donors has been previously reported. 70 Moreover, several case reports have suggested the occurrence of donor-derived HLA Ab production that was possibly associated with platelet transfusion refractoriness in these patients. 71, 72 Although cellular immunity has been the main focus of the studies in SCT for decades, a revision of the role of humoral immunity may be warranted.
